## LYMPHOMA

#### Pathology, Diagnosis and Treatment

Major advances have occurred in almost every aspect of the diagnosis and treatment of lymphoma in recent years. Our understanding of the molecular biology and genetics of the disease has increased exponentially, and significant developments in imaging of this malignancy have resulted in earlier and more accurate diagnosis. At the same time, advances in therapeutic immunology have led to the development of several new treatment options.

This landmark new text describes these advances in a single concise volume, placing them in the context of daily clinical practice. Introductory chapters review epidemiology, prognostic factors, imaging and therapeutic immunology. These are followed by chapters on each lymphoma subtype, dealing comprehensively with all aspects of the diagnosis and treatment of the disorder.

#### Unique features

- Pathology and cytogenetics information is fully integrated into the discussion of each disease entity, enabling the reader to review all the key diagnostic information for each disorder in one place.
- Treatment algorithms are provided for each lymphoma subtype to guide the reader through the decision-making process for first- and second-line treatment strategies.

Highly illustrated in full color throughout and written and edited by the leading authorities in the field, *Lymphoma: Pathology, Diagnosis and Treatment* provides all the information needed to diagnose and manage these complex disorders.

**Robert Marcus** is Consultant Haematologist at Addenbrooke's NHS Foundation Trust, and Assistant Lecturer in Pathology, University of Cambridge.

John Sweetenham is Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Director of Clinical Research at the Cleveland Clinic Taussig Cancer Center.

Michael Williams is the Byrd S. Leavell Professor of Medicine and Professor of Pathology, and Director of the Hematologic Malignancy Program, Hematology/Oncology Division and Cancer Center of the University of Virginia School of Medicine.

# LYMPHOMA

## Pathology, Diagnosis and Treatment

Edited by

Robert Marcus MB FRCP FRCPath Addenbrooke's NHS Foundation Trust, Cambridge

John W. Sweetenham DM FRCP Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Michael E. Williams MD FACP University of Virginia School of Medicine, Charlottesville



> CAMBRIDGE UNIVERSITY PRESS Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo

Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK

Published in the United States of America by Cambridge University Press, New York

www.cambridge.org Information on this title: www.cambridge.org/9780521865449

© Cambridge University Press 2007

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2007

Printed in the United Kingdom at the University Press, Cambridge

A catalog record for this publication is available from the British Library

ISBN 978-0-521-86544-9 hardback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

> To ERH "sapere aude" and JMG "il miglior fabbro" Robert Marcus

> To my patients and colleagues, from whom I have learned so much John Sweetenham

To my family, patients and colleagues, with gratitude Michael Williams

## **CONTENTS**

List of contributors	<i>page</i> ix
Preface	xiii

#### Part I LYMPHOMA OVERVIEW

1	Epidemiology Eleanor V. Willett and Eve Roman	3
2	Pathology and cytogenetics Andrew Wotherspoon, German Ott, Eugenia Haralambieva and Andreas Rosenwald	12
3	Imaging Ashley S. Shaw and Adrian K. Dixon	19
4	Prognostic factors for lymphomas Guillaume Cartron and Philippe Solal-Céligny	32
5	Clinical trials in lymphoma Thomas M. Habermann and Susan M. Geyer	55
6	Therapeutic immunology Neil L. Berinstein	68

#### Part II LYMPHOMA SUBTYPES

7	Hodgkin's lymphoma Stephanie Sasse and Andreas Engert	89
8	Follicular lymphoma Kristian Bowles, Daniel Hodson and Robert Marcus	111
9	MALT lymphoma and other marginal zone lymphomas Emanuele Zucca and Francesco Bertoni	126
10	Small lymphocytic lymphoma and its variants Peter Hillmen	141

#### Contents

11	Mantle cell lymphoma Martin Dreyling and Michael E. Williams	154
12	Diffuse large B-cell lymphoma John W. Sweetenham	168
13	Burkitt's and lymphoblastic lymphomas Alan S. Wayne and Wyndham H. Wilson	182
14	Central nervous system lymphoma Andrés J. M. Ferreri and Lisa M. DeAngelis	200

15	T-cell lymphoma Mujahid A. Rizvi, Andrew M. Evens, Beverly P. Nelson and Steven T. Rosen	215
16	Cutaneous lymphoma Julia Scarisbrick and Sean Whittaker	233
17	Lymphoma in the immunosuppressed Michele Spina, Robert Marcus and Umberto Tirelli	252
Inc	dex	266

## CONTRIBUTORS

#### Neil L. Berinstein

Toronto–Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada

#### Francesco Bertoni

Functional Genomics Unit, Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland

#### **Kristian Bowles**

Department of Haematology, Addenbrooke's NHS Trust, Cambridge CB2 2QQ, UK Current address: Norfolk & Norwich NHS Trust, Norwich NR4 7UY, UK

#### **Guillaume Cartron**

Equipe EA 3853, Immuno-Pharmaco-Genétique des Anticorps Thérapeutiques, Université François Rabelais, 37000 Tours, France

#### Lisa M. DeAngelis

Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA

#### Adrian K. Dixon

Department of Radiology, Addenbrooke's NHS Trust, Cambridge CB2 2QQ, UK

#### Martin Dreyling

University Hospital Grosshadern, Department of Internal Medicine III, Ludwig Maximilians University, 81377 Munich, Germany

ix

#### List of contributors

#### **Andreas Engert**

First Department of Internal Medicine, University Hospital Cologne, 50924 Cologne, Germany

#### Andrew M. Evens

Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 303 E Superior Street, Chicago, IL 60611, USA

#### Andrés J. M. Ferreri

Medical Oncology Unit, Department of Oncology, San Raffaele H. Scientific Institute, Via Olgettina 60, 20132 Milan, Italy

#### Susan M. Geyer

Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA

#### Thomas M. Habermann

Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA

#### Eugenia Haralambieva

Institute of Pathology, University of Würzburg, Josef-Schneider-Str 2, Würzburg 97080, Germany

#### Peter Hillmen

Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK

#### **Daniel Hodson**

Department of Haematology, Addenbrooke's NHS Trust, Cambridge CB2 2QQ, UK

#### **Robert Marcus**

Department of Haematology, Addenbrooke's NHS Trust, Cambridge CB2 2QQ, UK

#### **Beverly P. Nelson**

Section of Hematopathology, Department of Pathology, Northwestern University Feinberg School of Medicine, 303 E Superior Street, Chicago, IL 60611, USA

#### German Ott

Institute of Pathology, University of Würzburg, Josef-Schneider-Str 2, Würzburg 97080, Germany

#### Mujahid A. Rizvi

Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 303 E Superior Street, Chicago, IL 60611, USA

#### Eve Roman

Epidemiology and Genetics Unit, Department of Health Sciences, University of York, York YO10 5DD, UK

#### Steven T. Rosen

Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 303 E Superior Street, Chicago, IL 60611, USA

#### Andreas Rosenwald

Institute of Pathology, University of Würzburg, Josef-Schneider-Str 2, Würzburg 97080, Germany

#### Stephanie Sasse

First Department of Internal Medicine, University Hospital Cologne, 50924 Cologne, Germany

#### Julia Scarisbrick

St John's Institute of Dermatology, Guy's and St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK

#### Ashley S. Shaw

Department of Radiology, Addenbrooke's NHS Trust, Cambridge CB2 2QQ, UK

#### Philippe Solal-Céligny

Centre Jean Bernard, 9 rue Beauverger, 72000 Le Mans, France

#### **Michele Spina**

Division of Medical Oncology A, National Cancer Institute, Via Pedemontana occidentale 12, 33081 Aviano (PN), Italy

#### List of contributors

#### John W. Sweetenham

Cleveland Clinic Foundation, Hematology and Oncology/R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA

#### Umberto Tirelli

Division of Medical Oncology A, National Cancer Institute, Via Pedemontana occidentale 12, 33081 Aviano (PN), Italy

#### Alan S. Wayne

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA

#### Sean Whittaker

St John's Institute of Dermatology, Guy's and St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK

#### Eleanor V. Willett

Epidemiology and Genetics Unit, Department of Health Sciences, University of York, York YO10 5DD, UK

#### Michael E. Williams

Hematology/Oncology Division, University of Virginia Health System, Jefferson Park Avenue, Charlottesville, VA 22908, USA

#### Wyndham H. Wilson

Lymphoma Therapeutics Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA

#### Andrew Wotherspoon

Department of Histopathology, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK

#### Emanuele Zucca

Lymphoma Unit, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland

### PREFACE

Why publish a book on lymphoma in 2007? Surely there are sufficient reviews, meetings and published educational symposia to make such a work redundant. Furthermore, doesn't instant access to online information make any work in print out of date before it appears?

The editors and authors of this work think not. We firmly believe that there is still a place for a clear summary of the diagnosis, staging and therapy of lymphoma in a single volume that reflects the advances in these areas which have taken place over the past five years. The problem with the plethora of information now available is that it is rarely set in a framework of understanding of the major challenges which still face those involved with the diagnosis and therapy of non-Hodgkin's and Hodgkin's lymphomas. We, and our patients, are confronted with many facts but little judgment. This work is our modest attempt to rectify this.

Accordingly the layout of the book should enable the reader to gain an understanding of patterns of disease, methods of staging, principles of new approaches to therapy, and interpretation of clinical trials and prognostic markers by reading the first part of the book. In the second part the reader will find separate succinct yet comprehensive reviews of the individual disease entities which make up the spectrum of diseases comprising the lymphomas. Here we have integrated pathology, molecular biology and therapy for each subtype into a single chapter; the reader will not need to flick backwards and forwards to gain a comprehensive understanding of, say, follicular or diffuse large B-cell lymphoma. Such an integration has posed significant editorial challenges, and has been made possible by a willingness

#### Preface

on the part of Dr Wotherspoon, Dr Rosenwald and co-workers to accept that their contributions on histopathology and molecular cytogenetics would be divided and distributed among the relevant chapters. The editors are most grateful for their support.

Each chapter is followed by a select bibliography rather than an exhaustive list of references. We feel that these date very quickly, take up disproportionate amounts of space and are better found by internet searches or perusal of current journals.

This book is intended for senior trainees and fellows in hematology and oncology, together with more experienced practitioners who regularly treat these disorders. It is not intended for those who may feel they could have written the chapters themselves. It is also not a book where the reader will find detailed descriptions of rarities seen once in a professional lifetime. The appearance of this volume comes at an opportune time: we have seen over the past five years a profound understanding of the pathology of lymphoma, the use of increasingly sophisticated imaging techniques, and the integration of monoclonal antibodies into standard therapy for NHL. Our hope is that these radical changes in the way we diagnose and treat lymphoma have been reflected in the book and will stand the reader in good stead even when newer data become available.

The editors express their sincere and heartfelt thanks to all the authors, who have, in the main, responded promptly to our comments and recommendations, and to all those at Cambridge University Press who have helped with this project: Richard Barling, who set the wheels of this vehicle in motion, and especially Betty Fulford and Deborah Russell, who kept it moving to its final destination whenever it threatened to stall.